A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines

Inclusion criteria: * Signed informed consent was required to be obtained prior to participation in the study. * Male and female patients \>= 18 years of age at the time of screening * CSU duration for \>= 6 months prior to screening (defined as the onset of CSU determined by the Investigator based on all available supporting documentation) * Diagnosis of CSU inadequately controlled by second generation H1-AHs at the time of baseline (Day 1) defined as: * The presence of itch and hives for \>= 6 consecutive weeks prior to screening despite the use of second generation H1-AHs during this time period * UAS7 score (range 0-42) \>= 16, ISS7 score (range 0-21) \>= 6 and HSS7 score (range 0-21) \>= 6 during the 7 days prior to baseline (Day 1) * Documentation of hives within three months before baseline (either at screening and/or at baseline; or documented in the patients' medical history) * Willing and able to complete an UPDD for the duration of the study and adhere to the study protocol * Patients were required to not have more than one missing UPDD entry (either morning or evening) in the 7 days prior to baseline (Day 1) Exclusion criteria: * Patients having a clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticaria * Other diseases with symptoms of urticaria or angioedem…